Judy W M Cheng

Summary

Affiliation: Long Island University
Country: USA

Publications

  1. ncbi Infection and atherosclerosis--focus on cytomegalovirus and Chlamydia pneumoniae
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA
    Ann Pharmacother 32:1310-6. 1998
  2. ncbi L-arginine in the management of cardiovascular diseases
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, 75 DeKalb Ave, Brooklyn, NY 11201 5497, USA
    Ann Pharmacother 35:755-64. 2001
  3. ncbi Recognition, pathophysiology, and management of acute myocardial infarction
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA
    Am J Health Syst Pharm 58:1709-18; quiz 1719-21. 2001
  4. ncbi Cytochrome p450-mediated cardiovascular drug interactions
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, New York, USA
    Heart Dis 2:254-8. 2000
  5. ncbi Bosentan
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, and Mount Sinai Medical Center, New York, NY 10029, USA
    Heart Dis 5:161-9. 2003
  6. ncbi Nesiritide: review of clinical pharmacology and role in heart failure management
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University and Mount Sinai Medical Center, New York, NY 10029, USA
    Heart Dis 4:199-203. 2002
  7. ncbi Pharmacotherapeutic options for the management of myocardial infarction
    Judy W M Cheng
    Mount Sinai Medical Center, One Gustave L Levy Place, Box 1211, New York, NY 10029, USA
    Expert Opin Pharmacother 3:1153-68. 2002
  8. ncbi Fondaparinux: a new antithrombotic agent
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, New York, USA
    Clin Ther 24:1757-69; discussion 1719. 2002
  9. ncbi Updates on cytochrome P450-mediated cardiovascular drug interactions
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, NY, USA
    Am J Ther 16:155-63. 2009
  10. ncbi Use of non-aspirin nonsteroidal antiinflammatory drugs and the risk of cardiovascular events
    Judy W M Cheng
    Long Island University, New York, NY, USA
    Ann Pharmacother 40:1785-96. 2006

Detail Information

Publications28

  1. ncbi Infection and atherosclerosis--focus on cytomegalovirus and Chlamydia pneumoniae
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA
    Ann Pharmacother 32:1310-6. 1998
    ..e, cytomegalovirus and Chlamydia pneumoniae) in atherogenesis, and studies supporting the potential beneficial effects of antibiotics or antiviral agents in the management of atherosclerotic disease...
  2. ncbi L-arginine in the management of cardiovascular diseases
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, 75 DeKalb Ave, Brooklyn, NY 11201 5497, USA
    Ann Pharmacother 35:755-64. 2001
    ..To examine the role of L-arginine in the management of cardiovascular diseases...
  3. ncbi Recognition, pathophysiology, and management of acute myocardial infarction
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA
    Am J Health Syst Pharm 58:1709-18; quiz 1719-21. 2001
    ..Greater understanding of the pathophysiology of ACS has led to strategies to limit the progression of atherosclerosis and to improve survival and function after an acute event...
  4. ncbi Cytochrome p450-mediated cardiovascular drug interactions
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, New York, USA
    Heart Dis 2:254-8. 2000
    ....
  5. ncbi Bosentan
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, and Mount Sinai Medical Center, New York, NY 10029, USA
    Heart Dis 5:161-9. 2003
    ..Therefore, it is anticipated that numerous drug interactions may occur. Patients should be advised to consult their physicians or pharmacists should they need to consume other prescription or nonprescription medications...
  6. ncbi Nesiritide: review of clinical pharmacology and role in heart failure management
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University and Mount Sinai Medical Center, New York, NY 10029, USA
    Heart Dis 4:199-203. 2002
    ..On-going studies target the examination of its long-term effects on mortality and morbidity and its pharmacoeconomic benefits to the healthcare system...
  7. ncbi Pharmacotherapeutic options for the management of myocardial infarction
    Judy W M Cheng
    Mount Sinai Medical Center, One Gustave L Levy Place, Box 1211, New York, NY 10029, USA
    Expert Opin Pharmacother 3:1153-68. 2002
    ....
  8. ncbi Fondaparinux: a new antithrombotic agent
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, New York, USA
    Clin Ther 24:1757-69; discussion 1719. 2002
    ....
  9. ncbi Updates on cytochrome P450-mediated cardiovascular drug interactions
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, NY, USA
    Am J Ther 16:155-63. 2009
    ..The principles in predicting drug interactions are also discussed...
  10. ncbi Use of non-aspirin nonsteroidal antiinflammatory drugs and the risk of cardiovascular events
    Judy W M Cheng
    Long Island University, New York, NY, USA
    Ann Pharmacother 40:1785-96. 2006
    ....
  11. ncbi Effect of nesiritide on renal function: a retrospective review
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 10029, USA
    Curr Med Res Opin 21:1857-63. 2005
    ..This study examined the effect of nesiritide on RF in patients evaluated in this NUE...
  12. ncbi Rosuvastatin in the management of hyperlipidemia
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, USA
    Clin Ther 26:1368-87. 2004
    ....
  13. ncbi Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention
    Judy W M Cheng
    Long Island University, Mount Sinai Medical Center, Box 1211, One Gustave L. Levy Place, New York, NY 10029-6574, USA
    Am J Health Syst Pharm 59:S5-14. 2002
    ..Large clinical trials strongly support the use of abciximab or eptifibatide, but not tirofiban, in patients undergoing PCI...
  14. ncbi A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA
    Clin Ther 28:666-78. 2006
    ..When used with nitrates, hydralazine (HYD) acts as an antioxidant and prevents development of nitrate tolerance...
  15. ncbi Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York City
    Larisa Chagan
    Division of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA
    BMC Complement Altern Med 5:4. 2005
    ..This survey also assessed the perceptions of users regarding the safety/efficacy of BBT, types of BBT used and potential BBT-drug interactions...
  16. ncbi Tezosentan in the management of decompensated heart failure
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, NY 10029, USA
    Cardiol Rev 13:28-34. 2005
    ..Clinical studies demonstrated mixed results for tezosentan regarding its efficacy and tolerability in the management of decompensated heart failure. The role or tezosentan in treating heart failure is yet to be defined...
  17. ncbi Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor
    LilyAnn Jeu
    Pharmacy Services, Veterans Affairs Medical Center, Bronx, New York, USA
    Clin Ther 25:2352-87. 2003
    ..However, because trials have lasted no longer than 12 weeks, the long-term effect of ezetimibe on cardiovascular morbidity and mortality remains to be determined...
  18. ncbi Use of erythropoietin in heart failure management
    Krista Caiola
    Mount Sinai Hospital, New York, NY 10029, USA
    Ann Pharmacother 38:2145-9. 2004
    ..CONCLUSIONS: In selected patients with severe, chronic HF, erythropoietin may be considered for functional improvement. However, routine use of this treatment strategy is not recommended until more data are available...
  19. ncbi Ranolazine for the management of coronary artery disease
    Judy W M Cheng
    Department of Pharmacy Practice, Long Island University, Brooklyn, New York, USA
    Clin Ther 28:1996-2007. 2006
    ..Ranolazine is a new class of antianginal agent. Unlike standard antianginal agents, it alters glucose and fatty acid metabolism for a different approach to the management of coronary artery disease...
  20. ncbi Glucose-insulin-potassium solution for acute myocardial infarction
    Jeffrey L Janiger
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, NY, USA
    Ann Pharmacother 36:1080-4. 2002
    ..Dosage, duration of treatment, and route of administration of GIK varied among studies. CONCLUSIONS: Until results from larger-scale studies become available, the routine use of GIK infusion in AMI patients is not recommended...
  21. ncbi Key articles and guidelines in pharmacotherapeutic management of arrhythmias
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, New York, USA
    Pharmacotherapy 24:248-79. 2004
    ..This list should be useful not only to practitioners and trainees in cardiovascular pharmacotherapy, but also to other clinicians as an update...
  22. ncbi Use of alternative pharmacotherapy in management of cardiovascular diseases
    Larisa Chagan
    Shore Health System, Easton, MD, USA
    Am J Manag Care 8:270-85; quiz 286-8. 2002
    ..John's Wort with digoxin). CONCLUSIONS: The benefits of APs as part of the treatment for CVD are controversial. Routine use is not recommended...
  23. ncbi Early experiences and clinical implications of drug-eluting stents: part 1
    Pang H Chong
    University of Illinois at Chicago, Chicago, IL, USA
    Ann Pharmacother 38:661-9. 2004
    ..To review the pathogenesis of in-stent restenosis and the evolution of drug-eluting stents (DES)...
  24. ncbi Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure
    Patricia A Howard
    Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS 66160 7231, USA
    Ann Pharmacother 40:1607-17. 2006
    ....
  25. ncbi Vernakalant in the management of atrial fibrillation
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Pharmacother 42:533-42. 2008
    ..To review the pharmacology and clinical evidence of the use of vernakalant in the management of atrial fibrillation (AF)...
  26. ncbi Pharmacoeconomic review of medical management of persistent asthma
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
    Allergy Asthma Proc 29:109-22. 2008
    ..Future economic analysis should focus on finding better ways to evaluate productivity lost due to asthma, in addition to hospitalization...
  27. ncbi Ambrisentan for the management of pulmonary arterial hypertension
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Ther 30:825-33. 2008
    ....
  28. ncbi Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2
    Pang H Chong
    University of Illinois at Chicago, Chicago, IL, USA
    Ann Pharmacother 38:845-52. 2004
    ..To review early clinical experience and future implications of drug-eluting stents (DES) in percutaneous coronary interventions...